Target Brew Time:
Summer of 2017

  • Donate Here

  • Contact Us

  • E-Newsletter

Ales for ALS 2017!

Now in its fifth year, Ales for ALS has raised over $1,250,000 for ALS research. Invitations for the 2017 program have been sent, if you are a brewer and are interested in participating, please read about the program below and feel free to contact us.

Corey Reich

Blend designed by Russian River's Vinnie Cilurzo, Bell's Brewery's John Mallet and Sierra Nevada's Ken Grossman
The 2015 hop blend was designed by Bear Republic's Rob Kent, Bell's Brewery's John Mallett, Sierra Nevada's Ken Grossman & Brian Grossman and Beachwood BBQ and Brewing's Julian Schrago.


Loftus Ranches and Hopunion have created Ales for ALS to support a very worthy cause - ALS research. They have offered participating brewers access to a proprietary hop blend, free of charge, in exchange for participation in Ales for ALS™. While we would like to work with every brewer in the United States (that would really raise a lot of research funding!) we are limited by the hop blend supply. Participating brewers receive an invitation from Loftus Ranches and Hopunion. Each will brew special beers with these hops and will donate a portion of the sales to ALS TDI, the world's leader in ALS research.

What is ALS? (AKA: Lou Gehrig's Disease)

Amyotrophic lateral sclerosis (ALS, Lou Gehrig's disease) is a progressive neurodegenerative disease that leads to paralysis,
due to the death of motor neurons in the spinal cord and brain.

  • There is no known cure for the disease.
  • The average person survives only 2-5 years following diagnosis.
  • About 5,000 people in the US are diagnosed with ALS each year.
  • There are about 30,000 people in the US diagnosed with ALS today.
  • The worldwide population of ALS patients is estimated at 450,000.

About ALS Therapy Development Institute

The ALS Therapy Development Institute (ALS TDI) and its scientists actively discover and develop treatments for ALS. We are the world's first and largest nonprofit biotech focused 100 percent on ALS research. Led by people with ALS and drug development experts, we understand the urgent need to slow and stop this disease. For more information, visit our website at